
Avacta Group Plc – LSE:AVCT.L
Avacta Group stock price today
Avacta Group stock price monthly change
Avacta Group stock price quarterly change
Avacta Group stock price yearly change
Avacta Group key metrics
Market Cap | 171.01M |
Enterprise value | 8.90B |
P/E | -12.27 |
EV/Sales | 2353.89 |
EV/EBITDA | -1028.74 |
Price/Sales | 23.35 |
Price/Book | 2.45 |
PEG ratio | 0.47 |
EPS | -0.24 |
Revenue | 32.9M |
EBITDA | -45.56M |
Income | -64.44M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -250.32% |
Oper. margin | -290.64% |
Gross margin | 76.16% |
EBIT margin | -290.64% |
EBITDA margin | -138.5% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAvacta Group stock price history
Avacta Group stock forecast
Avacta Group financial statements
Jun 2022 | 5.51M | -8.93M | -162.03% |
---|---|---|---|
Dec 2022 | 4.13M | -30.55M | -738.83% |
Jun 2023 | 11.88M | -11.53M | -97% |
Dec 2023 | 11.35M | -13.41M | -118.11% |
2027 | 28.71M | -30.33M | -105.66% |
---|
Analysts Price target
Financials & Ratios estimates
Jun 2022 | 45461000 | 9.47M | 20.85% |
---|---|---|---|
Dec 2022 | 92649000 | 74.21M | 80.1% |
Jun 2023 | 87748000 | 65.01M | 74.09% |
Dec 2023 | 73191000 | 51.38M | 70.21% |
Jun 2022 | -5.50M | -4.03M | 368K |
---|---|---|---|
Dec 2022 | -10.93M | -21.00M | 56.53M |
Jun 2023 | -8.04M | -7.35M | -561K |
Dec 2023 | -6.82M | -1.65M | -737K |
Avacta Group alternative data
Aug 2023 | 120 |
---|---|
Sep 2023 | 120 |
Oct 2023 | 120 |
Nov 2023 | 120 |
Dec 2023 | 120 |
Jan 2024 | 120 |
Feb 2024 | 120 |
Mar 2024 | 120 |
Apr 2024 | 120 |
May 2024 | 120 |
Jun 2024 | 120 |
Jul 2024 | 154 |
Avacta Group other data
Insider | Compensation |
---|---|
Mr. Tony Gardiner (1971) Chief Financial Officer, Company Sec. & Executive Director | $191,000 |
-
What's the price of Avacta Group stock today?
One share of Avacta Group stock can currently be purchased for approximately $126.4.
-
When is Avacta Group's next earnings date?
Unfortunately, Avacta Group's (AVCT.L) next earnings date is currently unknown.
-
Does Avacta Group pay dividends?
No, Avacta Group does not pay dividends.
-
How much money does Avacta Group make?
Avacta Group has a market capitalization of 171.01M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 140.83% to 23.25M US dollars.
-
What is Avacta Group's stock symbol?
Avacta Group Plc is traded on the LSE under the ticker symbol "AVCT.L".
-
What is Avacta Group's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Avacta Group?
Shares of Avacta Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Avacta Group's key executives?
Avacta Group's management team includes the following people:
- Mr. Tony Gardiner Chief Financial Officer, Company Sec. & Executive Director(age: 54, pay: $191,000)
-
How many employees does Avacta Group have?
As Jul 2024, Avacta Group employs 154 workers, which is 28% more then previous month and 28% more then previous quarter.
-
When Avacta Group went public?
Avacta Group Plc is publicly traded company for more then 21 years since IPO on 8 Sep 2003.
-
What is Avacta Group's official website?
The official website for Avacta Group is avacta.com.
-
How can i contact Avacta Group?
Avacta Group can be reached via phone at +44 1904 217070.
Avacta Group company profile:

Avacta Group Plc
avacta.comLSE
154
Biotechnology
Healthcare
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Wetherby, LS23 7FA
:
ISIN: GB00BYYW9G87
CUSIP: G2967N117